Past Events
October 23, 2023: Opportunities & Challenges in Small Molecule Therapeutics
Anjali Kumar, Head of Business Development, Cellarity
Dean Brown, SVP & Head of Discovery Sciences, Jnana Therapeutics
Elena Diez Cecilia, Sr Director, External Innovation DPDS, Janssen R&D at J&J
Sudhakar Garad, Global Head of Chemical & Pharmaceutical Profiling, Novartis Institutes for BioMedical
Research
Moderated by Ronak Savla, Director, Strategic Ventures, Catalent Pharma Solutions
September 18, 2023: Harnessing Your Investments: Doing More with Less
Katy Georgiadis, Sr Consultant, Program Leader, Halloran Consulting Group
Kiran Reddy, Sr Managing Director, Blackstone Life Sciences
Liz Reczek, CEO, Neutron Therapeutics
Omar Khalil, Partner, Sante Ventures
Moderated by Katie McCarthy, Chief Innovation Officer, Halloran Consulting Group
June 13, 2023: Implications of the Inflation Reduction Act
Erin Mistry, Chief Commercial Officer, Cormedix
Jaclyn Martin, Market Access, Bayer Pharmaceuticals
Ned Sharpless, Former Director, NCI, & Jupiter Bioventures
Tess Cameron, Principal, RA Capital
Moderated by Imran Nasrullah, VP & Head, Collaborate to Cure Hub US, BD & L, Bayer
May 2, 2023: What you Don't Know CAN Kill you: The Importance of Risk Management
Alejandra Carvajal, SVP, Chief Legal Officer, Mersana Therapeutics
Ed Downey, Enterprise Risk Management, Danforth Advisors
Robert Forrester, Co-founder & Director, IDRx, Inc.
Tamara Joseph, Chief Legal Officer, Spero Therapeutics
Moderated by Gregg Beloff, Managing Partner, Danforth Advisors
March 13, 2023: Managing Culture in Chaos
Art Krieg, UMASS Chan Medical School RNA Therapeutics Institute
Jacob Becraft, Co-founder & CEO, Strand Therapeutics
Marion Dorsch, President & CSO, Atavistik Bio
Moderated by Dave Melville, Founder & CEO, The Bowdoin Group
January 31, 2023: JP Morgan Healthcare Conference Recap
Abbas Kazimi, CBO, Nimbus Therapeutics
Jodie Morrison, CEO, Q32 Bio
John Whittaker, Managing Director, JP Morgan
Ramani Varanasi, Managing Director, ReVive Advisors
Moderated by Bruce Ledoux, Executive Director, JP Morgan
December 5, 2022: HOLIDAY COCKTAIL RECEPTION
November 15, 2022: Scaling at the Speed of Change
Frances Johnson, COO, Viewpoint Molecular Targeting
John McCabe, CFO, Orna Therapeutics
Molly Robb, Managing Partner, Diversified Search
Rob MacDougall, CEO, MarathonLS
Moderated by Joe Goldberg, National Life Sciences Industry Consulting Leader,
RSM US
October 18, 2022: Data Ownership
Guarav Singal, Physician, Brigham & Women's Hospital
Glenn Cohen, Deputy Dean, Harvard Law School
Jared Kesselheim, Managing Partner, Transformational Capital
Moderated by Julia Hesse, Partner, Healthcare Group, Choate Hall & Stewart LLP
September 12, 2022: Virtual Clinical Trials: Are they here to Stay?
Amanda McEwen, VP, Clinical Development, Elevian Therapeutics
Jennifer Cormier, SVP, Clinical Operations, PepGen
Laurie Halloran, President & CEO, Halloran Consulting Group, Inc
Moderated by Sean Wall, PPD, part of Thermo Fisher Scientific
June 6, 2022: Opportunities & Challenges with Cell & Gene Therapies
Tina Liu, Co-Founder, Skylark Bio
Lantz Mackey, Cell Therapy Development, Novartis
Tino Quintero, Chief Commercial Officer, Locus Biosciences
Chandra Ramanathan, EIR, MassGeneral Brigham
Moderated by Elizabeth Woo, VP & General Manager, Cell & Gene Therapies,
Thermo Fisher Scientific
April 28, 2022: The Challenges of Being a Public Company
Gregg Beloff, Managing Director, Danforth Advisors
Aoife Brennan, CEO, Synlogic, Inc
Scott Hansen, Head, Life Sciences, Venture Banking, Pacific Western Bank
Ivana Liebisch, CEO & President, Vigil Neuroscience
Moderated by Bruce Booth, Partner, Atlas Venture
March 15, 2022: Therapeutic Interventions for Healthy Aging
Tom Hughes, CEO, Navitor Pharmaceuticals
Joan Mannick, Co-founder and CEO, Tornado Therapeutics
Moderated by Jens Eckstein, Partner, Apollo Health Ventures
February 3, 2022: Cultivating the Next Generation
Abe Ceesay, President, Cerevel Therapeutics
Paula Soteropoulos, Chairman of the Board, Ensoma
Alan Walts, Venture Partner, Advent Life Sciences
Moderated by Dave Melville, Founder & CEO, The Bowdoin Group
December 1, 2021: Holiday Cocktail & Wine Tasting Reception
November 16, 2021: The Pros & Cons of Controversial FDA Approvals
Art Krieg, CSO & Founder, Checkmate Pharmaceuticals
Christine McSherry, CEO, Casimir LLC
Erin Mistry, SVP Payer Strategy, Government Affairs & Trade, Cormedix
Martin Tolar, CEO, Alzheon
Moderated by Katie Brandt, Director, Caregiver Support Services & Public Relations, Mass General
Hospital Frontotemporal Disorders Unit
November 2, 2021: Cybersecurity Awareness: Protecting Yourself & Your Company
Ileana van der Linde, Executive Director, JP Morgan Cybersecurity Awareness
Global Program
October 18, 2021: The Rising Asymmetry in Deal Terms across our Ecosystem
John Delyani, CBO, Repertoire Immune Medicines
Lauren Foster, Director, MIT Life Sciences Technology Licensing Team
Michal Preminger, Head, Johnson & Johnson Innovation
Moderated by Brian Goldstein, Partner, Choate Hall & Stewart
September 13, 2021: Long-Term Planning in a Bull Market
Mike Gilman, CEO, Arrakis Therapeutics
Scott Hansen, EVP & Head of Life Sciences Venture Banking, Pacific Western Bank
Holly Whittemore, CFO, Nimbus Therapeutics
Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities
June 15, 2021: The SPAC Attack
Gregg Beloff, Managing Director, Danforth Advisors
Jason Meyenburg, CEO, Gemini Therapeutics
Geoff Meyerson, CEO & Co-founder, Locust Walk
May 11, 2021: The Future of RNA Therapies
Frank DeRosa, CTO, Translate Bio
Robert Meehan, Sr. Director, Clinical Development, Moderna
Jennifer Petter, Founder & CSO, Arrakis Therapeutics
Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities
April 7, 2021: Tax Policy Changes
Adam Frank, Head of Wealth Management, JP Morgan Securities
Fred Gordon, Sr. Director, National Tax, RSM
Moderated by Chris Cavallo, Partner, Tax Services, RSM
March 15, 2021: The Future of the JPM Healthcare Conference
Angus Grant, Chief Business Executive, BeiGene
Lis Leiderman, CFO & Head of Corporate Development, Decibel Therapeutics
Moderated by David Ke, Managing Director, Investment Banking, JP Morgan Securities
February 23, 2021: Leadership during COVID
Chris Garabedian, CEO, Xontogeny
Jodie Morrison, CEO, Cadent Therapeutics
Ramani Varanasi, President & CEO, X-Biotix Therapeutics
Moderated by Jennifer Reilly, President & COO, Safety Partners
October 13, 2020: Fundraising during a Pandemic (part 2)
Doug Carlson, CFO, Ikena Oncology
Nilesh Kumar, Partner, Novo Ventures
Scott Hansen, EVP, Head of Life Sciences, Pacific Western Bank
Brian Gallagher, Partner, Abingworth
September 24, 2020: Fundraising during a Pandemic
Stuart Chaffee, CBO, Praxis Medicines
Brian Gallagher, Partner, Abingworth
Keith Dionne, CEO, Casma Therapeutics
John Gustofson, Managing Director, AbbVie Ventures
February 3, 2020: Top Considerations when Engaging a Potential Strategic Partnership
Mary Lynne Hedley, President & COO, Tesaro
Briane Fenton, CBO, Translate Bio
Maude Tessier, CBO, Ikena Oncology
Moderated by Imran Nasrullah, Director, Strategic Partnering, BD & L, Boehringer-Ingelheim
December 2019: Building your C-Suite
Stuart Chaffee, CBO, Praxis Medicines
Michelle Doig, Partner, Omega Funds
Chris Robinson, Chief Talent Officer, Third Rock Ventures
Moderated by Keiran English, Partner, Spencer Stuart
October 2019: The Evolving Role of Artificial Intelligence & Blockchain Technology in Drug Discovery
Rosana Kapellar, EIR, Google Ventures
Arthur Hiller, Chief Corporate Development Office, Nuritas
Bennett Moore, Lead Digital Asset Resource, RSM US
Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities
September 2019: The Nuts & Bolts of Company Formation
Paulina Hill, Partner, Omega Funds
Samantha Truex, CEO, Quench Bio
Brian Goldstein, Partner, Choate Hall & Stewart
Scott Hansen, Managing Director, Pacific Western Bank
Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities
May 2019: Charles River Fever: Is a Cambridge Address Necessary for Success?
Robert Urban, Former/Retired Global Head, Johnson & Johnson Innovation, LLC
Jim Broderick, CEO, Palleon Pharmaceuticals
Paula Cloghessy, Chief Human Resources Officer, Translate Bio
Dave Melville, CEO & Founder, The Bowdoin Group
Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities
March 2019: Measuring Readiness and Preparing your IPO
Reenie McCarthy, CEO, Stealth Biotherapeutics
John Maxwell, CFO, Aquestive Therapeutics
Gregg Beloff, Managing Director, Danforth Advisors
Moderated by Greg Schernecke, Partner at Dechert LLP
February 2019: Company Growth & Evolution of the Board
Praveen Tipirneni, CEO, Morphic Therapeutics
Bill Collins, Partner, Life Sciences Practice at Goodwin
Bruce Rycklik, Managing Partner at Park Square Executive Search
Moderated by Bruce Ledoux, JP Morgan Securities
December 2018: Policy, Pricing & Patient Affordability: A Discussion on Reimbursement
Amitabh Chandra, Harvard Business School and Harvard Kennedy School of Government
Jamey Millar, GlaxoSmithKline
Moderated by Bruce Ledoux, JP Morgan Securities
October 2018: Patent Strategy & Management: IP Diligence for Companies & Investors & Maximizing Portfolio ROI
John McDonald, Biogen
Paul Burgess, Translate Bio
Karen Sinclair, Harvard University
Moderated by Andrea Reid, Dechert LLP
September 2018: The Evolution of Finance
Steve Robinette, Atlas Ventures
David Ke, JP Morgan
Michal Preminger, J&J Innovation Center
Brian Goldstein, Choate, Hall & Stewart LLP
Moderated by Bruce Ledoux, JP Morgan Securities
May 2018: Structuring of Equity Compensation Models
Jeb Keiper, Nimbus Therapeutics
Paula Cloghessy, Translate Bio
Anne Longmire, JP Morgan Securities
Ram Kumar, Radford
Moderated by Bruce Ledoux, JP Morgan Securities
April 2018: Analysis of Oligonucleotides: Pros & Cons of Various Analytical Platforms
David Citerone, Frontage Laboratories
Jing Li, Alnylam Pharmaceuticals
February 2018: Tax Reform and its Implications to the Biotech Executive
Adam Frank, JP Morgan Securities
Robert McDonald, Partner, RSM
Moderated by Bruce Ledoux, JP Morgan Securities
November 2017: Strategic vs IPO: A Point & Counterpoint Discussion
Ron Renaud, CEO, Translate Bio
Doug Fambrough, CEO, Dicerna Pharmaceuticals
Moderated by Bruce Ledoux, JP Morgan Securities
October 2017: Advances in Biomolecule Analysis: A CMC Perspective
X. Sunney Xie- Harvard University
Desiree Tsao- Momenta Pharmaceuticals
Min Zhao- Frontage Labs
June 2017: Maximizing Value in a Merger & Acquisition or IPO Transaction
Phil Ross, JP Morgan
April 2017: Approaches to Immunogenicity Validations and the Impact of the Data on Early Clinical Development
Kevin Carleton- inVentiv Health
Susan Sloan- Visterra, Inc.
March 2017: Real World Evidence: The Convergence of Commercial & Clinical
David Thompson- inVentiv Health
Paul Hodgkins- Vertex
Arthur Hiller- Antyllus Therapeutics
Bryan Katz- inVentiv Health
December 2016: Holiday Cocktail Party
November 2016: Investigations into ISR (Incurred Sample Reproducibility) Failures
Pierre-Yves Caron- inVentiv Health
Case Studies presented by Krista Condon (Eisai), Eric David (Biogen), Estela Skende (Sunovion),
Heidi Mangus (Agios), and Mark Milton (Novartis)
September 2016: Regulatory Strategy
Carolyn Finkle- inVentiv Health
Stephane Lamouche- inVentiv Health
June 2016: Bioanalytical Challenges in Gene & Cellular Therapies and Biotherapeutics
Lilian Yengi- Bluebird Bio
Thomas Oglesby- inVentiv Health
May 2016: Commercial Viability
Angus Bromley- inVentiv Health
Waynne Waterfield- inVentiv Health
Arthur Hiller- Commercial Strategy Consultant
March 2016: Use of Proteomics to Identify Biomarkers
Richard Lipscombe- Proteomics International
Ru Wei- Biogen
Sept 2015: QT Assessments in Early Phase Trials
Borje Darpo- iCardiac Technologies, Inc
Sherilyn Adcock- Worldwide Clinical Trials
June 2015: CRO Selection: What are you looking for in your CRO Partner?
Liyu Yang- Biogen
Jim Vath- Zafgen
Peter Benton- Worldwide Clinical Trials
March 2015: Use of Adaptive Protocols in Drug Development
Jim Gilbert- True North Therapeutics
Gordon Loewen- Forum Pharmaceuticals
Darrell Nix- Drug Development Consulting
Sept 2014: When Novelty is not Enough: Creating Value Early and Throughout the Development Process
Mike Murphy- Worldwide Clinical Trials
May 2014: Use of Radiolabeled Studies in your Development Program
Wim Tamminga- QPS
Eric Solon- QPS
Jan 2014: The New Draft FDA BMV Guidance
September 2013: Validation of Biomarkers in the Bioanalytical Lab
Juan Chavez- Biogen
Jeff Moran- QPS
June 2013: Development of Bioanalytical Strategies for Characterization of Antibody Drug Conjugates (ADCs)
Dawn Dufield- Pfizer
Seema Kumar- Pfizer
March 2013: Issues with Metabolites
Caroline Lee- QPS
Jan 2013: Challenges in Alzheimer's Drug Development
Manfred Windisch- QPS (formerly JSW Life Sciences)
Oct 2012: Combining Autoradiography and Bioanalytical Techniques in Drug Discovery
Grace Poon- Syndexa
Eric Solon- QPS
June 2012: Preclinical Data Frontloading: An ADMET Perspective
Sanjeev Thohan, Novartis
Jian Yu- QPS
Jan 2012: New EMA BMV Guidance
Jeff Moran- QPS
Oct 2011: Protein analysis by LC-MS/MS
Joe Palandra- Pfizer
Ben van Baar- QPS
June 2011: Tissue Bioanalysis
Stacy Ho - Genzyme
Zamas Lam - QPS
March 2011: Dry Blood Spot
Krista Condon - Eisai
Jaap Weiling - QPS